JP2005507897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507897A5 JP2005507897A5 JP2003532038A JP2003532038A JP2005507897A5 JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5 JP 2003532038 A JP2003532038 A JP 2003532038A JP 2003532038 A JP2003532038 A JP 2003532038A JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5
- Authority
- JP
- Japan
- Prior art keywords
- silicon dioxide
- colloidal silicon
- composition
- pharmaceutical composition
- macrolide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 6
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 6
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- 239000007919 dispersible tablet Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 claims 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0123400.4A GB0123400D0 (en) | 2001-09-28 | 2001-09-28 | Organic compounds |
| PCT/EP2002/010890 WO2003028705A1 (en) | 2001-09-28 | 2002-09-27 | Pharmaceutical compositions comprising colloidal silicon dioxide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008309431A Division JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507897A JP2005507897A (ja) | 2005-03-24 |
| JP2005507897A5 true JP2005507897A5 (enExample) | 2005-12-15 |
Family
ID=9922916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532038A Withdrawn JP2005507897A (ja) | 2001-09-28 | 2002-09-27 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008309431A Expired - Lifetime JP5160386B2 (ja) | 2001-09-28 | 2008-12-04 | コロイド状二酸化ケイ素を含んでなる医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20040254210A1 (enExample) |
| EP (2) | EP1432408B8 (enExample) |
| JP (2) | JP2005507897A (enExample) |
| KR (1) | KR100626785B1 (enExample) |
| CN (3) | CN1561201A (enExample) |
| AR (2) | AR036643A1 (enExample) |
| AT (1) | ATE485813T1 (enExample) |
| BR (2) | BR0212922A (enExample) |
| CA (1) | CA2458455C (enExample) |
| CO (1) | CO5390072A1 (enExample) |
| CY (2) | CY1111119T1 (enExample) |
| DE (1) | DE60238131D1 (enExample) |
| DK (2) | DK1432408T3 (enExample) |
| EC (1) | ECSP024323A (enExample) |
| ES (2) | ES2560106T3 (enExample) |
| GB (1) | GB0123400D0 (enExample) |
| HU (1) | HU229991B1 (enExample) |
| IL (2) | IL160498A0 (enExample) |
| MX (1) | MXPA04002814A (enExample) |
| MY (1) | MY150060A (enExample) |
| NO (1) | NO333892B1 (enExample) |
| NZ (2) | NZ542273A (enExample) |
| PE (1) | PE20030602A1 (enExample) |
| PL (1) | PL209704B1 (enExample) |
| PT (2) | PT2193788E (enExample) |
| RU (1) | RU2322970C2 (enExample) |
| SI (1) | SI1432408T1 (enExample) |
| TW (1) | TWI242449B (enExample) |
| WO (1) | WO2003028705A1 (enExample) |
| ZA (1) | ZA200401300B (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| KR20050084559A (ko) * | 2002-09-17 | 2005-08-26 | 와이어쓰 | 경구 제형 |
| JPWO2004035089A1 (ja) * | 2002-10-09 | 2006-02-09 | 協和醗酵工業株式会社 | ホルモン依存性癌の治療剤 |
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| PL1901773T3 (pl) * | 2005-06-09 | 2012-09-28 | Hansa Medical Ab | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
| EP2094241A4 (en) * | 2006-11-14 | 2013-04-17 | Ariad Pharma Inc | ORAL FORMULATIONS |
| ES2602784T3 (es) | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
| HRP20151357T1 (hr) | 2008-05-02 | 2016-01-29 | Gilead Sciences, Inc. | Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa |
| CN101444494B (zh) * | 2008-12-31 | 2011-03-30 | 江苏大学 | 难溶性药物高效长效缓释制剂及其制法 |
| CN101444503B (zh) * | 2008-12-31 | 2011-02-02 | 江苏大学 | 一种水飞蓟宾高效长效制剂及其制法 |
| CN101439025B (zh) * | 2008-12-31 | 2011-05-11 | 江苏大学 | 一种水飞蓟素高效长效制剂及其制法 |
| ES2433076T3 (es) * | 2009-01-21 | 2013-12-09 | Mylan Inc. | Formulaciones disgregables de carbonato de lantano |
| US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| CA2780177A1 (en) | 2009-12-22 | 2011-06-30 | Abbott Laboratories | Abt-263 capsule |
| US20170087134A1 (en) * | 2010-07-12 | 2017-03-30 | Salix Pharmaceuticals, Ltd | Formulations of rifaximin and uses thereof |
| US20120045433A1 (en) * | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| JP6141188B2 (ja) | 2010-11-23 | 2017-06-07 | アッヴィ・インコーポレイテッド | アポトーシス誘導剤の塩および結晶の形態 |
| NZ708508A (en) | 2010-11-23 | 2016-06-24 | Abbvie Bahamas Ltd | Methods of treatment using selective bcl-2 inhibitors |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| DE102011052396A1 (de) * | 2011-08-04 | 2013-02-07 | Gelita Ag | Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung |
| KR101151890B1 (ko) * | 2011-08-11 | 2012-05-31 | 동아제약주식회사 | 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법 |
| PH12014500746A1 (en) | 2011-10-06 | 2019-07-17 | Novartis Ag | Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin |
| CN102793673A (zh) * | 2012-09-07 | 2012-11-28 | 中国药科大学 | 一种小檗碱磷脂复合物固体分散体及其制备方法 |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TW201503912A (zh) * | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| JP2016537345A (ja) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| CN103610646B (zh) * | 2013-12-05 | 2015-07-15 | 江苏奥赛康药业股份有限公司 | 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂 |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| WO2016135740A1 (en) | 2015-02-23 | 2016-09-01 | Natco Pharma Limited | Process for preparing stable oral compositions of everolimus |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| US10383860B2 (en) | 2015-07-28 | 2019-08-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same |
| JP6855470B2 (ja) * | 2016-05-27 | 2021-04-07 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| CN110072525B (zh) | 2016-09-30 | 2022-12-02 | 萨利克斯药品公司 | 利福昔明的固态分散形式 |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| KR20200024890A (ko) | 2017-07-05 | 2020-03-09 | 노파르티스 아게 | 신규한 약학적 조성물 |
| CN108125918B (zh) * | 2018-01-12 | 2020-06-23 | 杭州中美华东制药有限公司 | 依维莫司药物组合物 |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| WO2021245519A1 (en) * | 2020-06-01 | 2021-12-09 | Shilpa Medicare Limited | Fast dispersible pharmaceutical composition comprising capecitabine |
| WO2022219652A1 (en) * | 2021-04-17 | 2022-10-20 | Bdr Pharmaceuticals International Private Limited | Novel sublingual pharmaceutical formulations for everolimus |
| CN119523923A (zh) * | 2024-11-21 | 2025-02-28 | 华中药业股份有限公司 | 一种左炔诺孕酮片及其制备方法 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608080D0 (en) | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
| US5211958A (en) * | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US4920102A (en) * | 1988-04-18 | 1990-04-24 | Eli Lilly And Company | Method for treating gastrointestinal disorders |
| IT1246383B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per il mascheramento del sapore di farmaci |
| US5490987A (en) | 1991-07-03 | 1996-02-13 | The Upjohn Company | Tableting of colestipol hydrochloride |
| US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
| BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
| DE19544507B4 (de) | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| TR199801680T2 (xx) * | 1996-02-29 | 1999-02-22 | Fujisawa Pharmaceutical Co. Ltd. | Beta-laktam antibiyotik i�eren tabletler ve �retim y�ntemi. |
| JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
| DE69717810T2 (de) * | 1996-04-26 | 2003-09-18 | Shionogi & Co., Ltd. | S1452-tabletten mit schneller freisetzung |
| GB2318511A (en) | 1996-10-23 | 1998-04-29 | Eurand Int | Process for the preparation of a pharmaceutical composition for rapid suspension in water |
| NZ335737A (en) * | 1996-11-12 | 2000-09-29 | Pharmacia & Upjohn Ab | Compact member comprising a plurality of porous cellulose matrices (PCMs) |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| US6080427A (en) * | 1997-04-17 | 2000-06-27 | Bristol-Myers Squibb Company | Cefadroxil monohydrate tablet formulation |
| PT994697E (pt) | 1997-06-13 | 2005-02-28 | Wyeth Corp | Formulacoes de rapamicina para administracao oral |
| AU749623B2 (en) | 1998-03-26 | 2002-06-27 | Astellas Pharma Inc. | Sustained release preparations |
| FR2785538B1 (fr) * | 1998-11-06 | 2004-04-09 | Prographarm Laboratoires | Comprime a delitement rapide perfectionne |
| GB9826656D0 (en) * | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
| EP1161941A4 (en) * | 1999-03-15 | 2002-08-28 | Kaken Pharma Co Ltd | QUICKLY DISMANTLING TABLETS AND METHOD FOR THE PRODUCTION THEREOF |
| FR2793690B1 (fr) | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
| WO2000071117A1 (en) * | 1999-05-21 | 2000-11-30 | Kissei Pharmaceutical Co., Ltd. | Immediate release medicinal compositions for oral use |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| EP2281556A1 (en) | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
-
2001
- 2001-09-28 GB GBGB0123400.4A patent/GB0123400D0/en not_active Ceased
-
2002
- 2002-09-26 PE PE2002000948A patent/PE20030602A1/es not_active Application Discontinuation
- 2002-09-26 EC EC2002004323A patent/ECSP024323A/es unknown
- 2002-09-26 AR ARP020103642A patent/AR036643A1/es not_active Application Discontinuation
- 2002-09-27 IL IL16049802A patent/IL160498A0/xx unknown
- 2002-09-27 AT AT02774661T patent/ATE485813T1/de active
- 2002-09-27 MY MYPI20023631A patent/MY150060A/en unknown
- 2002-09-27 NZ NZ542273A patent/NZ542273A/en not_active IP Right Cessation
- 2002-09-27 CN CNA028190459A patent/CN1561201A/zh active Pending
- 2002-09-27 MX MXPA04002814A patent/MXPA04002814A/es active IP Right Grant
- 2002-09-27 NZ NZ531599A patent/NZ531599A/en not_active IP Right Cessation
- 2002-09-27 CN CN2010101174089A patent/CN101912392A/zh active Pending
- 2002-09-27 DK DK02774661.9T patent/DK1432408T3/da active
- 2002-09-27 BR BR0212922-1A patent/BR0212922A/pt not_active IP Right Cessation
- 2002-09-27 TW TW091122345A patent/TWI242449B/zh not_active IP Right Cessation
- 2002-09-27 KR KR1020047004628A patent/KR100626785B1/ko not_active Expired - Lifetime
- 2002-09-27 WO PCT/EP2002/010890 patent/WO2003028705A1/en not_active Ceased
- 2002-09-27 EP EP02774661A patent/EP1432408B8/en not_active Expired - Lifetime
- 2002-09-27 SI SI200230928T patent/SI1432408T1/sl unknown
- 2002-09-27 PT PT91778894T patent/PT2193788E/pt unknown
- 2002-09-27 CO CO02087099A patent/CO5390072A1/es not_active Application Discontinuation
- 2002-09-27 RU RU2004113205/15A patent/RU2322970C2/ru active
- 2002-09-27 CN CN2006101159063A patent/CN1951390B/zh not_active Expired - Lifetime
- 2002-09-27 ES ES09177889.4T patent/ES2560106T3/es not_active Expired - Lifetime
- 2002-09-27 ES ES02774661T patent/ES2354687T3/es not_active Expired - Lifetime
- 2002-09-27 PL PL367896A patent/PL209704B1/pl not_active IP Right Cessation
- 2002-09-27 PT PT02774661T patent/PT1432408E/pt unknown
- 2002-09-27 DK DK09177889.4T patent/DK2193788T3/en active
- 2002-09-27 BR BRPI0212922-1A patent/BRPI0212922B1/pt unknown
- 2002-09-27 JP JP2003532038A patent/JP2005507897A/ja not_active Withdrawn
- 2002-09-27 CA CA2458455A patent/CA2458455C/en not_active Expired - Lifetime
- 2002-09-27 DE DE60238131T patent/DE60238131D1/de not_active Expired - Lifetime
- 2002-09-27 EP EP09177889.4A patent/EP2193788B1/en not_active Expired - Lifetime
- 2002-09-27 HU HU0402394A patent/HU229991B1/hu unknown
- 2002-09-27 US US10/490,089 patent/US20040254210A1/en not_active Abandoned
-
2004
- 2004-02-18 ZA ZA200401300A patent/ZA200401300B/en unknown
- 2004-02-19 IL IL160498A patent/IL160498A/en active IP Right Grant
- 2004-03-26 NO NO20041270A patent/NO333892B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 JP JP2008309431A patent/JP5160386B2/ja not_active Expired - Lifetime
-
2010
- 2010-05-10 US US12/776,711 patent/US20100221331A1/en not_active Abandoned
- 2010-11-30 CY CY20101101091T patent/CY1111119T1/el unknown
-
2011
- 2011-06-13 US US13/158,921 patent/US20110306630A1/en not_active Abandoned
-
2012
- 2012-06-05 US US13/489,396 patent/US8617598B2/en not_active Expired - Lifetime
-
2014
- 2014-08-14 AR ARP140103055A patent/AR097341A2/es unknown
-
2016
- 2016-01-21 CY CY20161100068T patent/CY1117164T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507897A5 (enExample) | ||
| JP2009102341A5 (enExample) | ||
| CA2458455A1 (en) | Pharmaceutical compositions comprising colloidal silicon dioxide | |
| TWI254640B (en) | Use of a polymer of acrylic type as a disintegration agent | |
| US20200078354A1 (en) | Immediate release abuse deterrent tablet | |
| JP6067100B2 (ja) | 即放性乱用抑止医薬組成物 | |
| WO2004064752A3 (en) | Method of preparing sustained release microparticles | |
| JP5750847B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
| SG152240A1 (en) | Pharmaceutical compositions comprising an amphiphilic starch | |
| WO2004100857A3 (en) | Highly plastic granules for making fast melting tablets | |
| JP2006527184A5 (enExample) | ||
| WO2009043844A3 (en) | Orodispersible tablets | |
| JP2010518086A5 (enExample) | ||
| TW200635618A (en) | Solid dosage form comprising proton pump inhibitor and suspension made thereof | |
| JPWO2009151072A1 (ja) | 口腔内速崩壊錠及びその製造方法 | |
| JP2009507047A5 (enExample) | ||
| MX2008000099A (es) | Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones. | |
| WO2007071581A3 (de) | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten | |
| BG108516A (en) | Pharmaceutical formulation | |
| WO2003047552A3 (en) | Pharmaceutical composition comprising a 5ht1 receptor agonist | |
| HRP20100120T1 (hr) | Formulacije s valsartanom | |
| JP2014530802A5 (enExample) | ||
| CA2502731A1 (en) | Sustained release composition for oral administration of drugs | |
| JP2011516544A5 (enExample) | ||
| WO2005034857A3 (en) | Methods and compositions comprising diamines as new anti-tubercular therapeutics |